aprott Novo Nordisk A/S (NVO) secured the FDA approval for Wegovy, the weight loss version of the compound called semaglutide, for the indication of reducing risks of major cardiovascular adverse events ('MACE') in early March. Novo Nordisk is already enjoying significant commercial success with the type 2 diabetes version of semaglutide called Ozempic, and more recently, Wegovy is off to a strong start and would have higher uptake if it were not for the supply constraints as demand is exceeding supply. The ...

In the latest trading session, Novo Nordisk (NVO) closed at $126.16, marking a -1.93% move from the previous day. This change lagged the S&P 500's daily gain of 0.02%. On the other hand, the Dow registered a loss of 0.11%, and the technology-centric Nasdaq increased by 0.1%.The drugmaker's stock has dropped by 0.6% in the past month, exceeding the Medical sector's loss of 4.52% and the S&P 500's loss of 3.01%.Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings dis ...

The U.S. Senate has launched an investigation into the high price of Novo Nordisk's popular weight loss and diabetes drugs Ozempic and Wegovy in the United States, versus other countries where the drugs are sold.The investigation into the Danish drugmaker was announced by Sen. Bernie Sanders, the Vermont Independent who chairs the Health, Education, Labor and Pensions (HELP) Committee."The scientists at Novo Nordisk deserve great credit for developing these drugs that have the potential to be a game changer ...

Good news could be just around the corner for two drugmakers not named Novo Nordisk.Ozempic and Wegovy are the rock stars of the biopharmaceutical world. When celebrities talk about a prescription drug, it has reached the big time. And that's what has happened with Novo Nordisk's two blockbusters. The success of Ozempic and Wegovy has also helped Novo Nordisk become a rock star for investors. Shares of the big drugmaker have skyrocketed nearly 240% over the last three years.Don't worry if you think you've m ...

Here at Zacks, we offer our members many different opportunities to take full advantage of the stock market, as well as how to invest in ways that lead to long-term success.One of our most popular services, Zacks Premium offers daily updates of the Zacks Rank and Zacks Industry Rank; full access to the Zacks #1 Rank List; Equity Research reports; and Premium stock screens like the Earnings ESP filter. All are useful tools to find what stocks to buy, what to sell, and what are today's hottest industries.It a ...

It's not only spending its capital on developing new drugs.Hardly for the first time in recent weeks and months, Novo Nordisk (NVO 2.08%) had a good trading session on the stock market Monday. The company's shares enjoyed a more than 2% boost on the day, comparing favorably to the 0.9% rise of the S&P 500 index. Investors were cheered by the fact that the Denmark-based pharmaceutical upstart is maintaining its stock repurchase program.Stock buyback program updateNovo Nordisk said in a brief update that it h ...

These stocks probably won't be getting much cheaper.As investing legends like Warren Buffett probably know better than anyone, there's something satisfying about buying shares of a company you intend to hold for the rest of your career as an investor. By making a commitment to remaining patient for the long haul as the money trickles in, you're also demonstrating to yourself that you're serious about using the savvy investing strategies that it takes to improve your financial life in a durable fashion.Psych ...

Biotech stocks offer the possibility of groundbreaking medical advancements alongside the potential for explosive growth. While the sector carries inherent risks, a select group of biotech companies possesses the potential to deliver substantial returns in the coming years. It is no surprise that investors continue to turn to this sector as advancements in technology strengthen its growth prospects. From revolutionary gene therapies to cancer research, the possibilities are endless. Furthermore, the converg ...

Stock Performance - Novo Nordisk closed at $123 46, marking a -0 36% move from the previous day, lagging the S&P 500's daily gain of 0 03% [1] - Shares of the company lost 6 77% over the past month, underperforming the Medical sector's loss of 5 81% and the S&P 500's loss of 0 9% [1] Earnings and Revenue Expectations - Analysts expect Novo Nordisk to post earnings of $0 77 per share in the upcoming report, marking a year-over-year growth of 20 31% [1] - Revenue is forecasted to be $9 48 billion, indicating a 23 23% growth compared to the corresponding quarter of the prior year [1] - For the full year, analysts expect earnings of $3 33 per share and revenue of $42 billion, representing year-over-year growth of 23 33% and 24 6%, respectively [2] Analyst Estimates and Stock Performance - Recent revisions in analyst estimates reflect the latest near-term business trends, with positive revisions indicating optimism about the company's business and profitability [2] - Adjustments in estimates are directly associated with imminent stock price performance [2] - The Zacks Rank system, which incorporates estimate changes, has a track record of success, with 1 stocks delivering an average annual return of +25% since 1988 [3] Valuation Metrics - Novo Nordisk is currently traded at a Forward P/E ratio of 37 23, indicating a premium compared to its industry's Forward P/E of 13 85 [3] - The company has a PEG ratio of 2 06, higher than the industry average of 1 69, reflecting its expected earnings growth rate [3] Industry Overview - The Large Cap Pharmaceuticals industry, part of the Medical sector, currently has a Zacks Industry Rank of 195, placing it in the bottom 23% of over 250 industries [4] - The Zacks Industry Rank shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]

Key PointsNovo Nordisk has seen unprecedented success with its GLP-1 drugs Ozempic and Wegovy for Type 2 diabetes and obesity, respectively.Wegovy was used in a study of obese Type 2 diabetes patients with heart failure with preserved ejection fraction (HFpEF) against a placebo, resulting in conclusive improvements that met primary endpoints.Novo Nordisk seeks to expand its indications to include cardiovascular diseases and possibly neurological disorders.5 stocks we like better than Novo Nordisk A/SOzempic ...